J Biol Chem, Vol. 275, Issue 16, 11814-11823, April 21, 2000
The Mitochondrial Permeability Transition Augments
Fas-induced Apoptosis in Mouse Hepatocytes*
Etsuro
Hatano
§,
Cynthia A.
Bradham§,
Alexander
Stark§,
Yuji
Iimuro
§¶,
John J.
Lemasters
, and
David A.
Brenner
§**
From the Departments of
Medicine,
§ Biochemistry & Biophysics, and
Cell Biology & Anatomy, University of North Carolina,
Chapel Hill, North Carolina 27599
 |
ABSTRACT |
Tumor necrosis factor-
receptor 1 and Fas recruit overlapping signaling pathways. To clarify the
differences between tumor necrosis factor
(TNF
) and Fas pathways
in hepatocyte apoptosis, primary mouse hepatocytes were treated with
TNF
or an agonist anti-Fas antibody after infection with an
adenovirus expressing an I
B superrepressor (Ad5I
B). Treatment
with TNF
induced apoptosis in Ad5I
B-infected mouse hepatocytes,
as we previously reported for rat hepatocytes. Ad5I
B plus anti-Fas
antibody or actinomycin D plus anti-Fas antibody rapidly induced
apoptosis, whereas anti-Fas antibody alone produced little
cytotoxicity. The proteasome inhibitor (MG-132) and a dominant-negative
mutant of nuclear factor-
B-inducing kinase also promoted TNF
- and
Fas-mediated apoptosis. Expression of either crmA or a
dominant-negative mutant of the Fas-associated death domain protein
prevented TNF
- and Fas-mediated apoptosis. In addition, the caspase
inhibitors, DEVD-cho and IETD-fmk, inhibited TNF
- and Fas-mediated
apoptosis. In Ad5I
B-infected hepatocytes, caspases-3 and -8 were
activated within 2 h after treatment with anti-Fas antibody or
within 6 h after TNF
treatment. Confocal microscopy
demonstrated onset of the mitochondrial permeability transition (MPT)
and mitochondrial depolarization by 2-3 h after anti-Fas antibody
treatment and 8-10 h after TNF
treatment, followed by cytochrome
c release. The combination of the MPT inhibitors, cyclosporin A, and trifluoperazine, protected Ad5I
B-infected hepatocytes from TNF
-mediated apoptosis. After anti-Fas antibody, cyclosporin A and trifluoperazine decreased cytochrome c
release but did not prevent caspase-3 activation and cell-death. In
conclusion, nuclear factor-
B activation protects mouse hepatocytes
against both TNF
- and Fas-mediated apoptosis. TNF
and Fas recruit
similar but nonidentical, pathways signaling apoptosis. The MPT is
obligatory for TNF
-induced apoptosis. In Fas-mediated apoptosis, the
MPT accelerates the apoptogenic events but is not obligatory for them.
 |
INTRODUCTION |
Apoptosis, a morphologically and biochemically distinct form of
cell death, is an important physiologic process in both normal development and in pathological processes. Two death factors, Fas
ligand and tumor necrosis factor-
(TNF
),1 bind to their
receptors and induce apoptosis, killing the cells within hours (1).
Apoptosis controlled by such death receptor pairs can cause tissue
destruction (2). Hepatocyte apoptosis, mainly induced by death domain
receptor ligands such as Fas ligand and TNF
, is implicated in
several experimental and human liver diseases including viral
hepatitis, alcoholic hepatitis, acute liver failure,
ischemia/reperfusion injury, diseases of the bile ducts,
graft-versus-host disease, and hepatocellular carcinoma (3).
The TNF receptor family includes Fas, the receptor for Fas ligand, and
the two TNF
receptors (TNFR) (1). Upon binding to Fas ligand, Fas
forms a complex with the associated protein, Fas-associated death
domain protein (FADD), which directly binds and activates caspase-8.
Recent studies showed that FLICE-associated huge protein interacts with
FADD and caspase-8 (4). FLICE-associated huge protein may control
apoptosis at the level of caspase activation. TNFR1 interacts with the
adaptor protein TNFR-associated death domain protein (TRADD) that
recruits FADD, which again directly activates caspase-8. TNF
also
induces other signaling pathways via TRADD including the protein kinase
receptor interacting protein and TNF receptor-associated factor 2 (TRAF2). TNF
activates the mitogen-activated protein kinase kinase
kinase, NF-
B-inducing kinase (NIK), via either protein kinase
receptor interacting protein or TRAF2 (5, 6). NIK in turn
phosphorylates and activates the I
B kinase (IKK) complex (7-9).
IKKs phosphorylate I
B, targeting it for NF-
B activation
(10-12).
Recent studies indicate that NF-
B activation by TNF
protects
cells from TNF cytotoxicity (13-15). TNF
binding to the TNF receptor potentially both initiates apoptosis and activates NF-
B, which suppresses apoptosis by induction of NF-
B-responsive genes, including TRAF1, TRAF2, and the inhibitor of apoptosis proteins (16).
The expression of the I
B superrepressor by an I
B
(S32A, S36A)-expressing adenovirus (Ad5I
B), which blocks NF-
B
activation, sensitizes primary rat hepatocytes to TNF
-mediated
apoptosis (17). Furthermore, TNF
-mediated cytotoxicity is enhanced
by the addition of inhibitors of protein or RNA synthesis
(cyclohexamide and actinomycin D) (18).
Fas induces NF-
B binding activity in certain, but not all, cell
types. Fas can stimulate the DNA binding activity of NF-
B in a
variety of tumor cells irrespective of their sensitivity or resistance
to Fas-mediated cytotoxicity (19). Another report showed that the
activation of NF-
B can induce target gene expression that rescues
TNF
- but not Fas-mediated apoptosis in T24 cell lines (13). However,
whether NF-
B is activated in Fas-mediated apoptosis in nontumor
cells, such as hepatocytes, is not clear. Anti-Fas antibody injection
into mice induces severe liver failure with apoptosis of hepatocytes
(2). However, anti-Fas antibody alone induces apoptosis in less than
20% of the cultured hepatocytes in vitro, whereas all cells
were killed by anti-Fas antibody in the presence of actinomycin D or
cycloheximide (20, 21). These results suggest that cultured mouse
hepatocytes may express protective proteins against apoptosis.
Furthermore, Fas-mediated apoptosis was delayed in hepatocytes during
liver regeneration in mice (22). This suggests that TNF
may act as
one of the protective factors against Fas-mediated hepatocyte
apoptosis, because initiation of liver regeneration requires TNF
.
Perhaps TNF
-induced activation of NF-
B protects hepatocytes from
Fas-mediated apoptosis.
Mitochondria play a key role in the regulation of apoptosis (23-26).
Opening of the mitochondrial permeability transition (MPT) pore, which
is regulated by members of the Bcl-2 family, causes the release of
soluble proteins, such as cytochrome c and
apoptosis-inducing factor, from the intermembrane space. Inhibitors of
MPT pore opening, including cyclosporin A (CsA), block apoptosis in
some systems (27, 28). The MPT is an essential component in the
signaling pathways in TNF
-mediated cytotoxicity in the L929 line of
mouse fibroblast (29) and TNF
-induced apoptosis in rat hepatocytes (17). Anti-apoptotic Bcl-2 family proteins reside in mitochondria and
can prevent the MPT. Bcl-xL/Bcl-2 prevented the release of cytochrome
c, yet other aspects of mitochondrial dysfunction still transpired and cells died (30), suggesting that the release of
cytochrome c may not be required for cell death. Some
studies using nonhepatic cells demonstrate that the translocation of
cytochrome c from mitochondria to cytosol does not require a
mitochondrial transmembrane depolarization (31-33), whereas others
show that mitochondrial depolarization accompanies cytochrome
c release (34). Thus, mitochondrial involvement and the role
of cytochrome c and MPT in apoptosis are still controversial.
The purpose of this study was to elucidate the differences between Fas
and TNF
pathways in hepatocyte apoptosis and the roles of NF-
B
activation and MPT in Fas-mediated apoptosis. The results show that
NF-
B activation has a protective role in not only TNF
- but also
Fas-mediated apoptosis. Furthermore, we show that Fas agonistic
antibody induces the MPT, which accelerates apoptosis, but is not
essential for it.
 |
MATERIALS AND METHODS |
Primary Hepatocyte Cultures--
About 8-week-old C57Bl6 male
mice were anesthetized with ketamine/acepromazine malate administered
by intraperitoneal injection. Hepatocytes were then isolated by a
retrograde, nonrecirculating in situ collagenase perfusion
of livers cannulating through the inferior vena cava by a procedure
modified from Moldeus et al. (35). Livers were first
perfused in situ with an oxygenated 0.5 mM EGTA
containing calcium-free salt solution (8 ml/min, 37 °C for 5 min),
followed by perfusion with solution containing 0.04% collagenase D
(Roche Molecular Biochemicals) for 10 min. The liver was then gently
minced on a Petri dish and filtered with polyamide mesh (I 003 Y NITEX
3-60/45, TETKO Inc., NY). Hepatocytes were washed two times and
centrifuged at 50 × g for 2 min. Cell viability was
consistently >90% as determined by trypan blue exclusion. Hepatocyte
cultures contained less than 1% Kupffer cells and the stellate cells
as determined by fluorescein isothiocyanate-labeled latex beads (1 µm, Polysciences, Warrington, PA) and autofluorescence, respectively.
5 × 105 cells were plated on 6-well plates coated
with mouse collagen type I in Waymouth's medium containing 10% fetal
bovine serum, 0.1 µM insulin, and 0.1 µM
dexamethazone. 1.5 × 106, 2.5 × 106, or 8 × 106 cells were plated on a
60-, 100-, or 150-mm dish, respectively. After 2 h, the culture
was washed with phosphate-buffered saline and changed to hormonally
defined medium (HDM) containing 0.1 µM insulin, 2 mM L-glutamine, 5 µg/ml transferrin, 3 µM selenium, and 10 nM free fatty acids in
RPMI basal medium. Cells were infected with recombinant adenoviruses in
HDM containing 30 plaque-forming units/cell for 2 h at 37 °C
and then changed to HDM containing recombinant murine TNF
(R&D
Systems, Minneapolis, MN), Jo-2 (Pharmingen, San Diego, CA), or other
treatments. All animals received humane care in compliance with the
guidelines of the University of North Carolina.
Adenoviruses--
The adenovirus 5 variants Ad5I
B, Ad5LacZ,
Ad5
FADD and Ad5crmA, expressing HA-I
B
(S32A, S36A),
-galactosidase, a truncated form of FADD, and crmA, respectively,
have been described elsewhere (17, 36). The Ad5 vector expressing
NIK (Ad5
NIK) was constructed by cre-lox recombination as
described (37). An insert from pCDNA-HA2101 (deletion of amino
acids 1-623, a gift from Dr. G. Natoli) (6) was subcloned into the
shuttle vector pAdlox using standard techniques, and the construct was
confirmed by restriction digests. Expression of the
NIK construct
was confirmed with a luciferase reporter gene assay in monkey kidney
fibroblasts (COS-7, ATCC-CRL-1651, American Type Culture Collections)
as described previously (36) and Western blotting using a mouse anti-HA
monoclonal antibody (Babco, Berkeley, CA). Briefly, When COS cells
reached subconfluence on 6-well culture plates, the cells were
transfected with 3 µg of DNA and 1 µg of (
B)3-Luc, a reporter
plasmid containing three copies of the NF-
B binding site (38), using
LipofectAMINE (Life Technologies, Inc.). Twenty-four h after
transfection, medium was replaced with Dulbecco's modified Eagle's
medium containing 10% fetal bovine serum with or without 20 ng/ml of
TNF
. After a 5-h incubation, cellular extracts were prepared using
enhanced luciferase assay reagents (Analytical Luminescence, San Diego, CA). Some cells were infected with Ad5
NIK 24 h after
transfection of (
B)3-Luc, were stimulated, and were harvested as
described the above.
Measurement of Apoptosis--
For quantitation of cell viability
(presented as mean ± S.E.), cells were infected and treated as
described above. After 17-20 h of TNF
or Jo-2 treatment, cell
viability was determined by exclusion of trypan blue. Viable cells were
counted in three different 200× power fields, and the percentage of
treated viable cells to untreated viable cells was determined as a
percentage of control viability. For propidium iodide nuclear staining,
cells were fixed in 3:1 methanol/acetic acid, stained with 10 µg/ml
popidium iodide, and viewed with an Olympus fluorescence microscope
using a rhodamine filter set. Hepatocyte cell death was confirmed as
apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) (Roche Molecular Biochemicals). TUNEL staining was
performed according to the manufacture's instructions. Positive
(apoptotic) cells were counted in three different 200× power fields.
To assess DNA ladder formation, 2 × 106 cells were
digested overnight at 37 °C in 0.5 mg/ml proteinase K, 0.5%
sarcosyl in phosphate-buffered saline, treated with 10 µg of RNase
for 1 h at 37 °C, gently extracted with phenol and chloroform,
and analyzed on 2% agarose gels. Amino-4-trifluoromethyl courmarin
(AFC) release assays for caspase-3 and -8 activities were performed
using the FluorAce kit (Bio-Rad) according to the manufacturer's
instructions. Briefly, whole cell lysates were combined with 25 µM z-DEVD-AFC or IETD-AFC (Enzyme and Systems Products,
Livermore, CA) and were incubated 2 h at 37 °C. The change in
fluorescence (excitation at 370 nm and emission at 490 nm) was
monitored at 1-h intervals, converted to picomoles of AFC released by
using a standard curve, and normalized for protein concentration.
Nuclear Extract Preparation and Electrophoretic Mobility Shift
Assay--
Nuclear protein extracts were prepared from primary mouse
hepatocytes as described previously (17, 36). Protein-DNA binding reactions were carried out for 20 min on ice using 5 µg of nuclear extract and 32P-labeled DNA probes for the NF-
B
consensus binding site (39). Complexes were separated by
electrophoresis on nondenaturing 5% acrylamide gels and assayed by
autoradiography and PhosphorImager analysis (Molecular Dynamics,
Sunnyvale, CA). For supershift assays, 8 µg of antibody against p65
or p50 subunit of the NF-
B complex (Santa Cruz Biotechnology, Santa
Cruz, CA) were added to the reaction mixture, and the incubation time
was extended for an additional 30 min.
Western Blot Analysis for Cytochrome c--
The preparation of
cytosolic S100-fractions and Western blot analysis was performed as
described previously (17). Briefly, S-100 fractions were prepared from
8 × 106 hepatocytes by differential centrifugation in
buffer containing 250 mM sucrose. Lysates containing 25 µg of protein was separated by electrophoresis on 15% acrylamide SDS
gels and transferred into nitocellulose membranes (Schleicher & Schuell). Equal loading was confirmed by Ponceau S staining. Cytochrome
c was detected using primary monoclonal anti-cytochrome
c antibody (Pharmingen, San Diego, CA) and secondary
anti-mouse horseradish peroxidase-conjugated antibody (Santa Cruz
Biotechnology). Proteins were detected with ECL detection reagents
(Amersham Pharmacia Biotech).
Confocal Microscopy--
Cell loading and confocal microscopy
were carried out as described previously (40). Briefly, 1-2 × 106 hepatocytes plated on collagen-coated 40-mm-diameter
glass coverslips were infected with Ad5I
B in HDM supplemented with
50 mM HEPES (pH 7.0) to stabilize pH during the confocal
measurements. The cells were loaded with 250 nM
tetramethylrhodamine methyl ester (TMRM, Molecular Probes, Eugene, OR)
and 1 µM calcein-acetoxymethyl ester (Molecular Probes)
in Krebs Ringer-Hepes buffer for 15 min at 37 °C. The coverslips
were mounted on a Nikon microscope (Nikon, Melville, NY) in HDM-HEPES
containing 100 nM TMRM, and the temperature was maintained
at 37 °C. The first image (time point 0) was then recorded.
Subsequently, TNF
or Jo-2 was added to the medium, and images were
collected at given time-points. Calcein and TMRM fluorescence were
excited with an argon laser through a double dichroic reflector at 488 and 568 nm, respectively. TMRM was imaged through a 590-nm-long path
emission filter using a Bio-Rad MRC-600 confocal system (Bio-Rad).
Calcein fluorescence was collected through a 515-560-nm band path
emission filter. A numerical aperture 1.4, 60× objective lens was
used, and pinholes were set to 4 in both channels. Laser attenuation
and power were set at 0.3% and low, respectively.
 |
RESULTS |
The I
B Superrepressor Sensitizes Mouse Hepatocytes to TNF
-
and Fas-mediated Apoptosis--
Hepatocytes are resistant to
TNF
-mediated apoptosis unless they are also treated with an
inhibitor of protein synthesis (i.e. cycloheximide), RNA
synthesis (i.e. actinomycin D) (18, 41), or NF-
B activity
(i.e. an I
B superrepressor) (17). To extend these studies
into Fas-mediated apoptosis, we switched to primary cultures of adult
mouse hepatocytes, because rat hepatocytes only express low levels of
Fas (42). TNF
alone had no cytotoxicity in primary mouse
hepatocytes, but actinomycin D (ActD) plus TNF
caused massive cell
death (Fig. 1, 16.2 ± 0.4%, % control viability at 17 h after treatment). Also, treatment of
Ad5I
B-infected mouse hepatocytes expressing the I
B superrepressor
with TNF
induced cell death (12.0 ± 1.1%). Cells expressing
I
B superrepressor but not treated with TNF
did not lose
viability. Furthermore, Ad5LacZ had a minimal effect on cell viability
after TNF
treatment (82.0 ± 2.5%), compared with noninfected
hepatocytes after TNF
.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 1.
The I B
superrepressor sensitizes mouse hepatocytes to
TNF - and Fas-mediated cell death. Primary
mouse hepatocytes were treated with TNF (30 ng/ml) or Jo2 (0.5 µg/ml) after Ad5I B infection (30 m.o.i.). Some cells were
pretreated with ActD (0.2 µg/ml) or MG132 (20 µM). Cell
viability was assessed after 17 h by a trypan blue exclusion test.
Data are shown as average percent viability ± S.E. of two to four
different experiments.
|
|
To study the role of NF-
B activation on Fas-mediated apoptosis, we
treated cells with anti-Fas agonist-like antibody Jo2. Ad5I
B plus
Jo2 (12.0 ± 1.2%) or ActD plus Jo2 (8.7 ± 0.9%) rapidly induced massive cell death, whereas Jo2 alone had low cytotoxicity (78.0 ± 11.5%). Furthermore, Jo2 did not induce significant cell death in Ad5LacZ-infected hepatocytes (75.0 ± 1.1%). The
cytotoxic effects of Jo2 were dose-dependent in mouse
hepatocytes expressing the I
B superrepressor (data not shown). The
Ad5I
B-infected hepatocytes treated with Jo2 displayed nuclear
condensation and fragmentation by propidium iodide staining,
characteristic of apoptosis (Fig. 2A, lower panel),
whereas uninfected cells displayed normal nuclear morphology after Jo2
treatment (Fig. 2A, upper panel). To confirm hepatocyte death as apoptosis, TUNEL assay was performed. Although TUNEL positive cells were minimal after TNF
or Jo2 treatment, significant positive hepatocytes were observed after TNF
or Jo2 treatment in ActD-sensitized or Ad5I
B-infected hepatocytes (Fig. 2B). These results were consistent with cytotoxicity
determined by the trypan blue extraction test. Furthermore, apoptosis
was confirmed by the detection of fragmented chromosome DNA in infected cells after exposure to TNF
or Jo2 (Fig. 2C). However, no
DNA fragmentation was observed in the uninfected cells after Jo2
treatment. We also documented the role of the I
B/NF
B system in
TNF
- and Fas-mediated apoptosis with a proteasome inhibitor, because
proteasome inhibitors block I
B
degradation and reduce NF-
B
activation (43). MG-132, a potent and specific proteasome inhibitor
(Fig. 1, MG-132 alone, 92.0 ± 4.6%), promotes TNF
- and
Fas-mediated apoptosis (9.0 ± 3.6% and 0%, respectively).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 2.
The I B
superrepressor sensitizes mouse hepatocytes to
TNF - and Fas-mediated apoptosis.
A, propidium iodide-stained images of noninfected
(upper panel), and Ad5I B-infected cells (lower
panel) at 12 h after Jo2 treatment (original magnification of
×600). Arrows indicate representative apoptotic nuclei.
B, TUNEL assay performed at 13 h after treatment.
Apoptotic positive cells were counted in three different 200× power
fields. Data are shown as average positive cells ± S.E. of two
different experiments. C, DNA ladder assay from cultured
hepatocytes (2 × 106 cells) collected 19 h after
treatment. Cytosolic DNA was isolated and subjected to 2% agarose gel
electrophoresis.
|
|
To examine whether Jo2 directly activates NF-
B, NF-
B DNA binding
activity was assessed by electrophoretic mobility shift assay using an
NF-
B binding site as probe. TNF
treatment for 30 min induced an
increase in NF-
B DNA binding activity (2.2-fold increase,
p < 0.001, versus untreated hepatocytes)
(Fig. 3, A and B).
Jo2 treatment also induced NF-
B binding activity (1.5-fold increase,
p < 0.005, versus untreated hepatocytes),
although to a less extent than TNF
. This activation was observed
even at 15 min after Jo2 treatment with the peak at 30 min after Jo2
(data not shown). The NF-
B complex activated by Jo2 treatment of
mouse hepatocytes was composed of p50-p65 dimers, as determined by
supershifts (Fig. 3A). These results show that TNF
and
Jo2 activate NF-
B in mouse hepatocytes and blocking NF-
B
sensitizes mouse hepatocytes to TNF
- and Fas-mediated apoptosis.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 3.
TNF or Fas activates
NF- B in primary mouse hepatocytes and
overexpression of dominant-negative mutant NIK sensitizes hepatocyte to
TNF - or Fas-mediated cell death.
A, NF- B DNA binding activity was assessed by an
electrophoretic mobility shift assay using NF- B binding sites as the
probe with nuclear extracts prepared after a 30-min incubation with
TNF or Jo2. For supershift assays, 8 µg of antibody against the
p65 or p50 subunit of the NF-kB complex were added to the reaction
mixture, and the incubation time was extended for an additional 30 min.
B, band intensity was quantified using phosphoimager
analysis. Data are shown as mean of net cpm ± S.E. of three
different experiments. C, a reporter gene assay was
performed using ( B)3-luc. NF- B activation was induced
by a 5-h incubation with 20 ng/ml TNF . Results from one
representative experiment performed in duplicate are shown.
D, the HA-tagged NIK was detected by Western blotting
using anti-HA antibody in whole extracts after Ad5 NIK infection.
E, Ad5 NIK-infected hepatocytes were untreated or treated
with TNF (30 ng/ml) or Jo2 (0.5 µg/ml). Cell viability was
assessed after 17 h by trypan blue exclusion test. Data are shown
as average percent viability compared with uninfected cells (con) ± S.E. of three different experiments.
|
|
Overexpression of Dominant-Negative Mutant NIK Sensitizes
Hepatocytes to TNF
- and Fas-mediated Apoptosis--
NIK has been
identified as a TRAF2-interacting protein that signals for NF-
B
activation (5). Adenovirus (Ad5
NIK)-mediated overexpression of the
C-terminal NIK fragment (NIK
2101) impaired the induction of NF-
B
by TNF
in a reporter gene assay in COS cells (Fig. 3C).
HA-tagged
NIK was expressed in primary mouse hepatocytes by
infection of Ad5
NIK at 10, 30, and 50 m.o.i. (Fig. 3D). Dominant-negative expression of NIK sensitized mouse
hepatocytes to TNF
- and Fas-mediated cell death (Fig.
3E). Cell death by apoptosis was confirmed by TUNEL assay
(31.7 ± 1.7, 45.0 ± 3.2, TUNEL positive cells/200× power
field 13 h after TNF
or Jo2 treatment in Ad
NIK-infected
hepatocytes, respectively). These results support a protective role for
NF-
B activation in TNF
- and Fas-mediated apoptosis and that NIK
is required for the activation of NF-
B by TNF
or Fas.
TNF
and Jo2 Induce Caspase Activation in Ad5I
B-infected
Hepatocytes with Different Time Courses--
To compare TNF
and Fas
signaling pathways in hepatocyte apoptosis, time courses for caspase-3
and casapase-8 activation were determined. Ad5I
B-infected
hepatocytes were treated with TNF
(30 ng/ml) or Jo2 (0.5 µg/ml)
and then lysed and assayed for caspase-3 and caspase-8. Caspase-3 was
activated 11-fold for 6 h after TNF
treatment with the peak of
the activity of 41-fold at 16 h after treatment (Fig.
4A). Caspase-8 was activated
14-fold at 8 h. In Jo2-treated hepatocytes expressing the I
B
superrepressor, caspase-3 was activated 32-fold at 90 min after
treatment, with the peak of 69-fold at 8 h after treatment (Fig.
4B). Also, a distinct early peak of caspase-8 activation was
observed 90 min after Jo2 treatment. At later time points, caspase-8
was induced to higher levels by TNF
than Fas. These results show
that these caspases were activated in both TNF
- and Fas-mediated
apoptosis but that Fas activated caspases earlier than TNF
.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 4.
TNF and Jo2 activate
caspase-3 and -8 in Ad5I B-infected hepatocytes
with different time courses. Ad5I B-infected hepatocytes were
treated with TNF (30 ng/ml) or Jo2 (0.5 µg/ml) and then lysed and
assayed for caspase 3 and 8 activity (A and B,
respectively) at 1-h intervals. Data are shown as average fold
increases of basal levels without treatment ± S.E. of three
different experiments performed in duplicate.
|
|
FADD, crmA, and Caspase Inhibitors Block TNF
- and
Fas-mediated Cell Death in Ad5I
B-infected Hepatocytes--
To
investigate the involvement of apoptotic signals from the complexes of
TNFR·TRADD·FADD and Fas·FADD and the role of proximal caspases,
primary mouse hepatocytes were infected with Ad5I
B together with
Ad5
FADD (30 m.o.i.) or Ad5crmA (30 m.o.i.) and then treated with
TNF
(30 ng/ml) or Jo2 (0.5 µg/ml). Ad5
FADD expresses a
truncated, dominant-negative mutant of FADD (44). Ad5crmA expresses
crmA, a serpin inhibitor of a subset of caspases including caspases-1
and -8 (45, 46). Adenovirus-mediated expression of
FADD and crmA
prevents TNF
- and Fas-mediated apoptosis (Fig.
5). To assess the role of apoptotic
protease cascade in hepatocyte apoptosis, cells were treated with
DEVD-cho (50 µM)(an inhibitor of caspase 3) or IETD-fmk
(50 nM)(an inhibitor of caspases-4, -5, and -8) together
with TNF
(30 ng/ml) or Jo2 (0.5 µg/ml). Caspase inhibitors,
DEVD-cho or IETD-fmk, clearly inhibit TNF
- and Fas-mediated
apoptosis (Fig. 5). These results indicate that Fas and TNFR1 appear to
utilize similar or at least partially overlapping pathways including
FADD, caspase-3, caspase-8, and/or caspase-1.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 5.
FADD, crmA, and caspase
inhibitors block TNF - and Fas-mediated cell
death in Ad5I B-infected hepatocytes.
Primary mouse hepatocytes were infected with Ad5I B and then treated
with TNF (30 ng/ml) or Jo2 (0.5 µg/ml). Some hepatocytes were
infected with Ad5 FADD (30 m.o.i.) or Ad5CrmA (30 m.o.i.) or also
treated with DEVD-cho (50 µM) or IETD-fmk (50 nM). Cell viability was assessed after a 17-h treatment by
a trypan blue exclusion test. Data are shown as average percent
viability ± S.E.
|
|
TNF
and Jo2 Induce the MPT and Mitochondrial Depolarization in
Ad5I
B-infected Hepatocytes with Different Time Courses--
Primary
mouse hepatocytes were treated with TNF
(30 ng/ml) or Jo2 (0.5 µg/ml) after Ad5I
B infection (30 m.o.i.) and then loaded with
calcein to monitor the MPT and TMRM to monitor mitochondrial depolarization. Their fluorescence was monitored simultaneously in
living cells on a heated platform by confocal microscopy. Before treatment with Jo2, each TMRM-labeled mitochondrion corresponded to a
dark void in the calcein image, showing that the mitochondria were
polarized and impermeable to low molecular weight solutes (Fig.
6, upper left panel). At
3 h after treatment of Jo2, some mitochondria filled with calcein
fluorescence (Fig. 6, middle left panel), demonstrating
permeabilization of the inner mitochondrial membrane, corresponding to
the onset of the MPT. Simultaneously, these mitochondria lost TMRM
fluorescence, indicating depolarization (Fig. 6, middle right
panel). Finally, after 3.5 h of exposure to Jo2, there was
hepatotoxicity with extravasation of calcein (Fig. 6, lower left
panel). In contrast to Jo2 treatment, TNF
treatment induced MPT
and mitochondrial depolarization at 8-10 h in mouse hepatocytes (data
not shown). This TNF
result was similar to previous studies in
primary rat hepatocytes (17). These results show that MPT is induced in
both TNF
- and Jo2-mediated apoptosis but at different time
courses.

View larger version (82K):
[in this window]
[in a new window]
|
Fig. 6.
Jo2 induces the MPT and mitochondrial
depolarization in Ad5I B-infected
hepatocytes. Primary mouse hepatocytes were treated with Jo2 (0.5 µg/ml) after Ad5I B infection (30 m.o.i.) and then loaded with
calcein (left panel) to monitor the MPT and TMRM
(right panel) to monitor mitochondrial depolarization.
Calcein and TMRM fluorescence was monitored simultaneously over time in
living cells by confocal microscopy.
|
|
The Combination of CsA and Trifluoperazine (TFZ) Blocks TNF
- but
Not Fas-mediated Cell Death in Ad5I
B-infected Hepatocytes--
CsA,
an immunosuppressive cyclic oligopeptide, specifically blocks the MPT
and has been shown to prevent cell injury in several kinds of models
(40, 47). TFZ also blocks the MPT and prevents mitochondrial
depolarization, ATP depletion, and cell death (48). Hepatocytes
overexpressing I
B superrepressor were treated with TNF
or Jo2 in
the presence of CsA (5 µM) and TFZ (12.5 µM). Confocal studies showed that TMRM and calcein
distributions did not change between 8 (Fig.
7A) and 12 h (Fig.
7B) in TNF
-treated hepatocytes. Similarly, these
distributions did not change between 7 (Fig. 7C) and 13 h (Fig. 7D) in Jo2-treated hepatocytes. These results indicate that CsA plus TFZ block mitochondrial depolarization and MPT
in TNF
- and Fas-treated hepatocytes.

View larger version (131K):
[in this window]
[in a new window]
|
Fig. 7.
CsA plus TFZ blocks the MPT induced by
TNF or Jo2. Primary mouse hepatocytes
were treated with TNF (30 ng/ml) or Jo2 (0.5 µg/ml) with CsA (5 µM) plus TFZ (12.5 µM) after Ad5I B
infection (30 m.o.i.) and then loaded with calcein to monitor the MPT
and TMRM to monitor mitochondrial depolarization. These fluorescences
were monitored simultaneously over time in living cells by confocal
microscopy. A and B, 8 and 12 h after TNF
treatment, respectively. C and D, 7 and 13 h
after Jo2 treatment, respectively.
|
|
To test the ability of CsA plus TFZ to protect against TNF
- and
Fas-mediated apoptosis, primary mouse hepatocytes were infected with
Ad5I
B and then treated with TNF
(30 ng/ml) or Jo2 (0.5 µg/ml)
with and without CsA (5 µM) and/or TFZ (12.5 µM). CsA alone partially inhibits TNF
- and
Fas-mediated apoptosis (Fig.
8A). Furthermore, the
combination of CsA and TFZ significantly protects Ad5I
B-infected
hepatocytes from TNF
-mediated apoptosis but not from Fas-mediated
apoptosis. Although multiple concentrations of CsA (1-10
µM) and TFZ (2.5-25 µM) were tested, the
maximal protective effect of CsA plus TFZ on TNF
- and Fas-mediated
apoptosis were observed at the above concentrations.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 8.
The combination of CsA and TFZ blocks
TNF - but not Fas-mediated cytochrome
c release and cell death in
Ad5I B-infected hepatocytes. A,
primary mouse hepatocytes were infected with Ad5I B and then treated
with TNF (30 ng/ml) or Jo2 (0.5 µg/ml) with or without CsA (5 µM) and/or TFZ (12.5 µM). Cell viability
was assessed at 20 h after treatment by a trypan blue exclusion
test. Data are shown as average percent viability ± S.E.
B, primary mouse hepatocytes were treated with TNF (30 ng/ml) or Jo2 (0.5 µg/ml) with or without CsA (5 µM)
plus TFZ (12.5 µM) after Ad5I B infection (30 m.o.i.).
S-100 fractions were prepared at the indicated time points and analyzed
for cytochrome c content by Western blotting. C,
primary mouse hepatocytes were treated with TNF (30 ng/ml) or Jo2
(0.5 µg/ml) with CsA (5 µM) alone, TFZ (12.5 µM) alone, or both after Ad5I B infection (30 m.o.i.).
S-100 fractions were prepared 8 or 4 h after TNF or Jo2
treatment, respectively, and analyzed for cytochrome c
content by Western blotting.
|
|
MPT Accelerates Fas-mediated Apoptosis--
Our previous study
showed that the MPT is required for TNF
-mediated cytochrome
c release and subsequent apoptosis in rat hepatocytes (17).
CsA plus TFZ blocked the TNF
-mediated MPT (Fig. 7, A and
B) and cell death (Fig. 8A) in mouse hepatocytes overexpressing the I
B superrepressor. Although CsA plus TFZ blocked the Fas-mediated MPT (Fig. 7, C and D), cell
death still occurred (Fig. 8A). Therefore, to assess the
relationship between MPT and cytochrome c release, S-100
fractions were prepared from TNF
- or Jo2-treated hepatocytes
overexpressing I
B superrepressor with or without CsA plus TFZ.
Primary mouse hepatocytes were treated with TNF
(30 ng/ml) or Jo2
(0.5 µg/ml) after Ad5I
B infection (30 m.o.i.). S-100 fractions
were analyzed for cytochrome c content by Western blotting.
TNF
induced cytochrome c release into the cytoplasm at
6 h after treatment (Fig. 8B). Jo2 induced cytochrome c release at 2 h and peaks at 4 h after treatment
(Fig. 8B). Thus, cytochrome c release follows the
MPT in AdI
B-infected hepatocytes after Jo2 exposure. The treatment
of CsA plus TFZ substantially decreased cytochrome c release
at 2 or 4 h after Jo2 treatment (Fig. 8B), whereas CsA
plus TFZ completely blocked TNF
-mediated cytochrome c
release (Fig. 8B). However, CsA alone or TFZ alone had no
effect on blocking cytochrome c release in TNF
- or
Fas-mediated apoptosis (Fig. 8C). In addition to cytochrome
c release, caspase-3 activation was suppressed at early time
points after Jo2 treatment in hepatocytes treated with CsA plus TFZ
(Fig. 9A). CsA plus TFZ blocked 70% of TNF
-induced cell death in Ad5I
B-infected
hepatocytes even at 24 h after treatment (Fig. 9B).
Treatment of CsA plus TFZ delayed the time of 50% Fas-mediated cell
death from about 8 to about 20 h (Fig. 9C).
Furthermore, confocal studies demonstrated that bleb formation and cell
shrinkage was observed at 16-18 h after Jo2 treatment despite blocking
the MPT (Fig. 9D), whereas some mitochondria remained
polarized. These results indicate that although the MPT is not required
for Fas-mediated apoptosis in hepatocytes, the MPT accelerates the
progression of apoptotic cell killing.

View larger version (69K):
[in this window]
[in a new window]
|
Fig. 9.
MPT accelerates Fas-mediated apoptosis.
A, Ad5I B-infected hepatocytes were treated with Jo2 (0.5 µg/ml) with/without CsA (5 µM) plus TFZ (12.5 µM) and then lysed and assayed for caspase 3 activities.
Representative data are presented as pmol/µg protein. B
and C, cell viability was assessed by a trypan
blue exclusion test after TNF (B) or Jo2 (C)
treatment. Data are shown as average percent viability ± S.E.
D, Fas-induced hepatotoxicity despite blocking the MPT.
Primary mouse hepatocytes were infected with Ad5I B and then treated
with Jo2 (0.5 µg/ml), CsA (5 µM), and TFZ (12.5 µM) and then loaded with calcein and TMRM. Calcein and
TMRM fluorescence was monitored simultaneously over time in living
cells by confocal microscopy. Bleb formation and cell shrinkage were
observed in the cell that the arrows indicate.
|
|
 |
DISCUSSION |
Fas agonistic antibody (Jo2) and TNF-
are potent mediators of
hepatoxicity in vivo and in cultured cells. In the present study, we demonstrated that (a) inhibition of NF-
B
activation by the I
B superrepressor by a proteasome inhibitor or by
a dominant-negative NIK sensitizes mouse hepatocytes to TNF
- and
Fas-mediated apoptosis; (b) both TNF
and Fas activates
NF-
B in primary mouse hepatocytes; (c) TNF
and Fas
recruit similar pathways including FADD, the activation of caspase-3
and caspase-8, the MPT, and cytochrome c release, but the
Fas signaling pathway for apoptosis is more rapid; (d)
inhibition of the MPT with CsA and TFZ blocks TNF
-mediated apoptosis, but delays rather than prevents Fas-mediated apoptosis; and
(e) inhibition of MPT markedly decreases cytochrome
c release and delays caspase-3 activation in Fas-mediated
apoptosis. These observations suggest that two pathways contribute to
Fas-mediated apoptosis and that the MPT contributes to an early and
more rapid pathway to apoptotic cell killing (Fig.
10).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 10.
Fas signaling pathway in primary mouse
hepatocytes. I B superrepressor, dominant-negative NIK, or
MG-132 (a proteasome inhibitor) sensitized hepatocytes to Fas-mediated
apoptosis. FADD, casapse-8, the MPT, and caspase-3 were involved in Fas
apoptotic signaling pathway as well as in the TNF signaling pathway.
When the MPT was blocked with CsA plus TFZ, Fas induces caspase-3 and
apoptosis via an MPT-independent pathway.
|
|
Anti-Fas antibody (Jo2) injection rapidly induces massive hepatocyte
apoptosis in mice in vivo (2). Nevertheless, many studies
using cultured mouse hepatocytes have shown that Fas-mediated apoptosis
requires the presence of an inhibitor of translation (cycloheximide),
an inhibitor of RNA synthesis (actinomycin D), or a protein kinase
inhibitor (H7) (20, 21). Consistent with these reports, anti-Fas
antibody alone has very low cytotoxicity in cultured mouse hepatocytes,
whereas Act D sensitizes hepatocytes to Fas-mediated apoptosis in this
study (Fig. 1). These results suggest that cultured mouse hepatocytes
may express protective proteins against apoptosis from Fas-mediated
apoptosis. NF-
B activation prevents TNF
toxicity in many cell
types (13-15), including hepatocytes (49). Thus we hypothesized that
NF-
B may also protect primary mouse hepatocytes from Fas-mediated apoptosis.
NF-
B is sequestered in the cytoplasm by inhibitory proteins, such as
I
B
, which mask the nuclear localization signal of NF-
B (50).
The phosphorylation of two serines 32 and 36 of I
B
by the IKK
complex, which includes IKK
, IKK
, and IKK
, triggers
polyubiquitination of I
B proteins, which targets them for rapid
proteasome-dependent degradation (7, 8, 10-12, 51). The
loss of I
B binding allows NF-
B to translocate to the nucleus and
activate NF-
B-dependent transcription. In this study we
selected three methods for inhibition of NF-
B activation: adenovirus-mediated expression of an I
B superrepressor and a dominant-negative mutant NIK, and a proteasome inhibitor, MG-132. Inhibition of NF-
B activation by any of these methods clearly sensitizes mouse hepatocytes to TNF
- and Fas-mediated apoptosis, whereas these treatments without TNF
or Fas stimulation have no
significant cytotoxicity (Figs. 1, 2B, and 3E).
Furthermore, mobility shift assays indicate that Jo2 induces NF-
B
DNA binding activity (1.5-fold increase) in cultured mouse hepatocytes,
even though this activity was weaker than TNF
-induced NF-
B DNA
binding activity (2.2-fold increase) (Fig. 2B). This
TNF
-induced NF-
B DNA binding activity is comparable to that in
myocytes (2.1-fold increase) (52). These results suggest that Fas
increases NF-
B DNA binding activity, which is mediated by activated
NIK, activated IKK, phosphorylated I
B, and subsequent I
B
degradation by proteasomes with translocation of NF-
B to the
nucleus. A previous study showed that Fas stimulates the DNA binding
activity of NF-
B in a variety of cells, irrespective of their
sensitivity or resistance to Fas-mediated cytotoxicity (19). However,
in our study, NF-
B activation had a protective effect in
Fas-mediated apoptosis in cultured mouse hepatocytes.
One of the protective proteins against apoptosis is inducible
nitric-oxide synthases. NO prevents apoptosis by suppressing the
increase of caspase-3-like activity (53). NO-mediating
S-nitrosylation of the cysteine-containing enzymes that
mediate apoptosis may regulate the balance between apoptosis and
necrosis (54). The mRNA of inducible nitric-oxide synthases is
regulated by NF-
B, and NO prevents hepatocyte apoptosis initiated by
the removal of growth factors or exposure to TNF
or anti-Fas
antibody (55-57). Therefore, inducible nitric-oxide synthases might be
an NF-
B-inducible protective gene mediating resistance to TNF
and
Fas cytotoxicity.
Ceramides have been implicated as a second messenger in signaling
pathways leading to apoptosis (58-61). A recent paper showed that
primary rat hepatocytes are resistant to ceramide-induced toxicity
(62). However, NF
B inactivation or ActD sensitize a rat hepatocyte
cell line to ceramide toxicity, suggesting that ceramide may act as a
downstream mediator of TNF
toxicity. On the other hand, it has been
reported that GD3 ganglioside, a product of ceramide, is required for
Fas- and ceramide-induced apoptosis (63), induces the MPT and apoptosis
in rat hepatoma cells (64), and directly induces the MPT in isolated
liver mitochondria (64, 65). Although significant cell-type-specific
differences exist in cell death pathway, further investigations will
determine the relationship between Fas, ceramides, and the MPT in hepatocytes.
A recent study defined two pathways for Fas-mediated apoptosis in
different cell types (66). In type I cells, caspase-8 is activated
within seconds and caspase-3 within 30 min, whereas in type II cells
cleavage of caspases is relatively delayed. Both cells showed similar
Fas-mediated apoptosis and loss of mitochondrial transmembrane
potential, but only in type II cells does overexpression of Bcl-2 or
Bcl-xL block caspase-8 and caspase-3 activation as well as apoptosis,
indicating type II cells are dependent on mitochondria. Our previous
study showed that the MPT is an essential component in TNF
-mediated
apoptosis in rat hepatocytes and functions upstream of caspase-3.
However, our present study demonstrates differences in signaling
pathways between TNF
- and Fas-mediated apoptosis in hepatocytes. The
time course in the activation of caspases by Fas was different from
those by TNF
. Activation of caspase-3 and -8 was within 2 h
after Jo2 treatment (Fig. 4, A and B), whereas TNF
activated caspase-3 and -8 after 6 h. This result is
consistent with the report that the Fas signaling pathway is more rapid
and strong in hepatocytes compared with TNF
(67). These results on
the activation of caspases by Fas indicate that primary mouse hepatocytes act predominantly as type II cells.
Several pieces of evidence implicate mitochondria in the process of
apoptosis. Cytoplasmic events including activation of protease cascades
and MPT participate in the control of nuclear apoptosis (24, 68, 69).
Whether the MPT is essential for cellular apoptosis remains
controversial, because some studies claim that cytochrome c
release during apoptosis occurs without mitochondrial depolarization
(68, 70), whereas other studies show the opposite (34). Here we show
cyclosporin A plus trifluoperazine prevents the MPT and cytochrome
c release by TNF
as well as apoptosis in mouse
hepatocytes, as described previously in rat hepatocytes (17). These
data suggest that mitochondria, especially the MPT, is essential for
hepatocyte apoptosis by TNF
in mice and rats.
However, the involvement of the MPT in Fas-mediated apoptosis has
remained elusive. Activation of caspase-1 precedes the disruption of
the mitochondrial inner transmembrane potential, but caspase-3 activation and nuclear apoptosis only occur in cells in which the
mitochondrial transmembrane potential is fully disrupted (71). This
indicates that the MPT is essential for apoptosis downstream of
caspase-1 and upstream of caspase-3. These human CEM-C7.H2 lymphoma
cells seem to be type II cells, as described above (66). In our study
cyclosporin A plus trifluoperazine prevented the MPT and markedly
decreased cytochrome c release by Fas, but apoptosis was not
blocked in mouse hepatocytes (Figs. 7, 8C, 9A,
and 9B). These results indicate that Fas induces the MPT,
which accelerates but is not necessary for apoptosis.
The mechanism by which activated caspase-8 recruits the mitochondria to
participate in apoptosis is cleaving and activating Bid. Bid then
translocates to the mitochondria to trigger cytochrome c
release (72, 73). Cytochrome c binds to Apaf1, which in turn
self-associates and binds procaspase-9. Transactivation of the
complexed procaspase-9 then activates downstream caspases. Our results
demonstrating Fas-induced MPT are consistent with an apoptotic pathway
that includes the mitochondria. However, Fas-mediated apoptosis is
intact in Apaf1 knockout T cells (74). Furthermore, while this
manuscript was under review, it was reported that Fas-mediated
apoptosis was delayed rather than prevented in Bid-deficient
hepatocytes (75). These results combined with our study indicate that
Fas signaling in hepatocytes activates both a mitochondrial independent
pathway and a mitochondrial dependent pathway of apoptosis (Fig.
10).
 |
ACKNOWLEDGEMENTS |
We thank Dr. Robert Currin and Dr. Ting Qian
for technical assistance with the confocal microscopy and Dr. Christian
Jobin for supplying the reagents.
 |
FOOTNOTES |
*
This work was supported by Research Fellowships of the Japan
Society for the Promotion of Science for Young Scientists (to E. H.), and National Institutes of Health Grants GM41804 (to D. A. B.), DK34987 (to D. A. B. and J. J. L.),
AA11605 (to D. A. B. and J. J. L.), DK37034 (to
J.J.L), and AG07218 (to J.J.L).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Present address: Dept. of Gastroenterological Surgery, Kyoto
University Graduate school of Medicine, Kyoto, 606-8507, Japan.
**
To whom correspondence should be addressed: C.B. 7080, University
of North Carolina at Chapel Hill, Chapel Hill, NC 27599. Tel.:
919-966-0650; Fax: 919-966-7468; E-mail: dab@med.unc.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
TNF, tumor necrosis
factor;
TNFR, tumor necrosis factor-a receptor;
FADD, Fas-associated
death domain protein;
TRADD, tumor necrosis factor-
receptor-associated death domain protein;
TRAF, tumor necrosis
factor-
receptor-associated factor;
NF-
B, nuclear factor
B;
NIK, NF-
B-inducing kinase;
IKK, I
B kinase;
AD5I
B, adenovirus
expressing I
B
superrepressor (532A, 536A);
MPT, mitochondrial
permeability transition;
CsA, cyclosporin A;
HDM, hormonally defined
medium;
HA, hemagglutinin;
TUNEL, terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling;
TMRM, tetramethylrhodamine
methyl ester;
ActD, actinomycin D;
m.o.i., multiplicity of infection;
TFZ, trifluoperazine;
AFC, amino-4-trifluoromethyl coumarin.
 |
REFERENCES |
| 1.
|
Nagata, S.
(1997)
Cell
88,
355-365[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Ogasawara, J.,
Watanabe-Fukunaga, R.,
Adachi, M.,
Matsuzawa, A.,
Kasugai, T.,
Kitamura, Y.,
Itoh, N.,
Suda, T.,
and Nagata, S.
(1993)
Nature
364,
806-809[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Galle, P. R.,
and Krammer, P. H.
(1998)
Semin. Liver Dis.
18,
141-151[Medline]
[Order article via Infotrieve]
|
| 4.
|
Imai, Y.,
Kimura, T.,
Murakami, A.,
Yajima, N.,
Sakamaki, K.,
and Yonehara, S.
(1999)
Nature
398,
777-785[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Malinin, N. L.,
Boldin, M. P.,
Kovalenko, A. V.,
and Wallach, D.
(1997)
Nature
385,
540-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Natoli, G.,
Costanzo, A.,
Moretti, F.,
Fulco, M.,
Balsano, C.,
and Levrero, M.
(1997)
J. Biol. Chem.
272,
26079-26082[Abstract/Free Full Text]
|
| 7.
|
Woronicz, J. D.,
Gao, X.,
Cao, Z.,
Rothe, M.,
and Goeddel, D. V.
(1997)
Science
278,
866-869[Abstract/Free Full Text]
|
| 8.
|
Cohen, L.,
Henzel, W. J.,
and Baeuerle, P. A.
(1998)
Nature
395,
292-296[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Zhao, Q.,
and Lee, F. S.
(1999)
J. Biol. Chem.
274,
8355-8358[Abstract/Free Full Text]
|
| 10.
|
DiDonato, J. A.,
Hayakawa, M.,
Rothwarf, D. M.,
Zandi, E.,
and Karin, M.
(1997)
Nature
388,
548-554[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Mercurio, F.,
Zhu, H.,
Murray, B. W.,
Shevchenko, A.,
Bennett, B. L.,
Li, J.,
Young, D. B.,
Barbosa, M.,
Mann, M.,
Manning, A.,
and Rao, A.
(1997)
Science
278,
860-866[Abstract/Free Full Text]
|
| 12.
|
Zandi, E.,
Rothwarf, D. M.,
Delhase, M.,
Hayakawa, M.,
and Karin, M.
(1997)
Cell
91,
243-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Van Antwerp, D. J.,
Martin, S. J.,
Kafri, T.,
Green, D. R.,
and Verma, I. M.
(1996)
Science
274,
787-789[Abstract/Free Full Text]
|
| 14.
|
Liu, Z. G.,
Hsu, H.,
Goeddel, D. V.,
and Karin, M.
(1996)
Cell
87,
565-576[CrossRef][Medline]
|